Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Recida Therapeutics

Request full access

Recida Therapeutics is a Biotechnology company

Menlo Park, United StatesFounded 2016Biotech & Life Sciences

About Recida Therapeutics

Recida Therapeutics operates as a clinical-stage biopharmaceutical company with a dedicated focus on creating anti-infective medications to combat multi-drug resistant infections. The company was established by Frazier Healthcare Partners in 2016 and officially launched in February 2019, with co-founders including James Ge, Vernon Jiang, George H. Talbot, and Paul Eckburg. The leadership team brings to the table significant experience in the development of antibiotics, including well-known drugs like doripenem, ceftaroline, and ceftolozane/tazobactam.

The company's business model is centered on the clinical development and subsequent commercialization of novel antibiotics. A key part of its strategy involves forming partnerships to advance its product pipeline. For instance, Recida has licensed the development and commercialization rights for its lead candidate, RC-01, from FUJIFILM Toyama Chemical Co. for all territories outside of Japan. Additionally, a partnership with MicuRx Pharmaceuticals, Inc. covers the development and commercialization of RC-01 in the greater China region. Funding for Recida's operations has been secured through a Series A financing round of $8.5 million led by Frazier Healthcare Partners and a grant of up to $4.4 million from CARB-X, a global non-profit partnership dedicated to accelerating antibacterial research and development.

Recida's primary product candidate is RC-01, a novel LpxC inhibitor designed to treat multidrug-resistant Gram-negative infections. The drug functions by inhibiting LpxC, a crucial enzyme for the survival of Gram-negative bacteria. This mechanism represents a new class of antibiotics, a significant development considering no new class of anti-gram-negative antibiotics has been successfully developed in over 65 years. RC-01 has demonstrated potent activity against a wide range of clinically relevant pathogens, including Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. A notable feature is its activity against highly resistant P. aeruginosa isolates from cystic fibrosis patients. In April 2019, Recida initiated a Phase I clinical trial in the United States to evaluate the safety, tolerability, and pharmacokinetics of RC-01. Preclinical studies showed a favorable safety profile, avoiding toxicities seen in previous LpxC inhibitors.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2016
Headquarters
Menlo Park, United States
Open positions
None listed
Dealroom signal
45.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Feb 2019 $8.5M $34M Frazier Healthcare Partners —
CONVERTIBLE✓Equity / VC Jul 2018 $5.7M — Undisclosed —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Recida Therapeutics website traffic

Latest recorded traffic for Recida Therapeutics is 0 monthly website visits.

Latest monthly visits0
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Recida Therapeutics in the Menlo Park ecosystem

Live from Dealroom

The Recida Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Frazier Healthcare Partners
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Menlo Park HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Recida Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Recida Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.